InsidersTradesSigma
Follow the VERACYTE INC stock price and the full directors' dealings record of the company, a publicly traded company based in United States. Shares are quoted on US US, under the authority of SEC (Form 4). Market capitalisation: €4.6bn. The latest transaction was filed on 4 June 2026 (Notice of proposed sale (Form 144)). Among the most active insiders: MARC STAPLEY. The full history is openly available.
Analysts rate VERACYTE INC Buy (bullish), based on 10 analysts. Average price target: US$55.60.
Informational score on this market. Our backtest validates the signal only on 8 EU venues; elsewhere (notably US markets) insider buys historically invert or do not hold. Not a recommendation.
Transparent value + quality ranking, distinct from the insider signal.
Fundamental view, insider signal, bull and bear case, synthesis.
AI-generated analysis. Opinion, not investment advice. Not backtested. Built from public filings and financials. No price target, no buy or sell recommendation.
1 of 1 declaration
Veracyte Inc is a molecular diagnostics company that provides tests to aid clinical decision-making in healthcare. It is listed on NASDAQ under the symbol VCYT.